• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超根治性手术在晚期上皮性卵巢癌中的应用提高了生存率:来自一家三级转诊中心的结果。

Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.

机构信息

Department of Obstetrics and Gynecology, Tampere University Hospital, Finland; Tays Cancer Centre, Tampere University Hospital, Finland.

Department of Obstetrics and Gynecology, Tampere University Hospital, Finland; Faculty of Medicine and Health Technology, Tampere University, Finland; Tays Cancer Centre, Tampere University Hospital, Finland.

出版信息

Gynecol Oncol. 2022 Jun;165(3):478-485. doi: 10.1016/j.ygyno.2022.03.023. Epub 2022 Apr 6.

DOI:10.1016/j.ygyno.2022.03.023
PMID:35397919
Abstract

OBJECTIVE

To compare survival rates of surgically treated advanced epithelial ovarian cancer patients before and after a programmatic change in surgical approach from standard surgery towards ultra-radical surgery.

METHODS

247 patients with FIGO stage IIIB-IV ovarian, tubal, and primary peritoneal carcinoma were operated during 2013-2019 either by primary or interval cytoreduction in Tampere University Hospital, Finland. Group 1 (n = 122) patients were operated during 2013 and February 2016. Group 2 patients (n = 125) were operated between March 2016 and March 2019, when a systematic change in surgical approach towards more extensive surgery was implemented.

RESULTS

The complete resection (R0) rate increased significantly from 17.2% (21/122) to 52.0% (65/125) within the study period (p < 0.001). The median progression-free survival (PFS) was 15.6 months vs 19.3 months (p = 0.037), and the median overall survival (OS) was 33.5 months vs 54.5 months in Groups 1 and 2, respectively (p = 0.028). Median OS for stage III patients in Group 1 was 36.1 months (95% CI 27.4-44.8) but could not be reached in Group 2 (p = 0.009). In Stage IV patients, OS was 32.0 months (16.4-47.7) and 39.3 months (24.8-53.8) in Group 1 and 2, respectively (p = 0.691). Multivariable Cox regression analysis revealed that OS was independently affected by the amount of residual tumor and complication grade.

CONCLUSIONS

The change of surgical approach towards maximal surgical effort improved both progression-free and overall survival. The survival benefit was unquestionable for stage III patients but did not reach statistical significance in stage IV patients.

摘要

目的

比较经程序性手术方式改变,由标准手术转为超根治性手术治疗后,上皮性卵巢癌晚期患者的生存率。

方法

2013 年至 2019 年,在芬兰坦佩雷大学医院对 247 例FIGO 分期为 IIIB-IV 期卵巢、输卵管和原发性腹膜癌患者进行了手术治疗,采用初次或间隔性肿瘤细胞减灭术。第 1 组(n=122)患者于 2013 年和 2016 年 2 月接受手术。第 2 组(n=125)患者于 2016 年 3 月至 2019 年 3 月接受手术,期间手术方式改为更广泛的切除。

结果

研究期间,完全切除(R0)率从 17.2%(21/122)显著提高到 52.0%(65/125)(p<0.001)。无进展生存期(PFS)的中位数为 15.6 个月对 19.3 个月(p=0.037),第 1 组和第 2 组的总生存期(OS)中位数分别为 33.5 个月和 54.5 个月(p=0.028)。第 1 组 III 期患者的中位 OS 为 36.1 个月(95%CI 27.4-44.8),但第 2 组无法达到(p=0.009)。IV 期患者的 OS 分别为 32.0 个月(16.4-47.7)和 39.3 个月(24.8-53.8)(p=0.691)。多变量 Cox 回归分析显示,OS 独立于残余肿瘤量和并发症分级。

结论

手术方式改为最大程度的手术努力,改善了无进展生存期和总生存期。III 期患者的生存获益是毋庸置疑的,但 IV 期患者未达到统计学意义。

相似文献

1
Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.超根治性手术在晚期上皮性卵巢癌中的应用提高了生存率:来自一家三级转诊中心的结果。
Gynecol Oncol. 2022 Jun;165(3):478-485. doi: 10.1016/j.ygyno.2022.03.023. Epub 2022 Apr 6.
2
Ultra-radical surgery versus standard-radical surgery for the primary cytoreduction of advanced epithelial ovarian cancer; long-term tertiary center experiences.超根治性手术与标准根治性手术治疗晚期上皮性卵巢癌的初次细胞减灭术:长期三级中心经验。
Eur J Obstet Gynecol Reprod Biol. 2024 Nov;302:125-133. doi: 10.1016/j.ejogrb.2024.09.005. Epub 2024 Sep 7.
3
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
4
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.在晚期上皮性卵巢癌中,初次肿瘤细胞减灭术时的微小残留病灶与间隔性肿瘤细胞减灭术时的完全肿瘤切除相比:一项生存分析。
Gynecol Oncol. 2020 Apr;157(1):209-213. doi: 10.1016/j.ygyno.2020.01.010. Epub 2020 Jan 15.
5
A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.晚期卵巢癌完全细胞减灭术后肿瘤负担、手术时机和复杂性的预后影响的多变量分析。
Gynecol Oncol. 2020 Sep;158(3):614-621. doi: 10.1016/j.ygyno.2020.06.495. Epub 2020 Jul 22.
6
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.一种新的晚期卵巢癌间歇肿瘤减灭术后残留病灶分类方法,可更好地区分肿瘤学结局。
Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7. doi: 10.1016/j.ajog.2019.05.006. Epub 2019 May 10.
7
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.初次肿瘤细胞减灭术与新辅助化疗后间隔肿瘤细胞减灭术治疗晚期卵巢癌的疗效比较。
Arch Gynecol Obstet. 2016 Jan;293(1):163-168. doi: 10.1007/s00404-015-3813-z. Epub 2015 Jul 22.
8
Ultra-radical surgery for advanced ovarian cancer: a retrospective cohort study in a tertiary referral cancer center in the UK.英国一家三级转诊癌症中心的一项回顾性队列研究:晚期卵巢癌的超根治性手术。
Minerva Obstet Gynecol. 2024 Aug;76(4):319-326. doi: 10.23736/S2724-606X.22.05179-X. Epub 2023 Apr 14.
9
Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.新辅助化疗可提高晚期上皮性卵巢癌的R0细胞减灭率,但不能改善最终结局。
Ann Surg Oncol. 2017 May;24(5):1330-1335. doi: 10.1245/s10434-016-5704-3. Epub 2016 Dec 19.
10
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗:生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.

引用本文的文献

1
Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.减瘤手术联合腹腔热灌注化疗治疗卵巢癌后的发病和死亡结局
J Clin Med. 2025 Mar 6;14(5):1782. doi: 10.3390/jcm14051782.
2
The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer.晚期卵巢癌患者完整10年队列的条件性、无复发生存和长期生存轨迹。
Acta Oncol. 2025 Mar 17;64:423-430. doi: 10.2340/1651-226X.2025.42994.
3
Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study.
在 PARP 抑制剂时代之前卵巢癌患者的预后因素和总生存期:OCRWE-芬兰研究。
Acta Oncol. 2024 Oct 16;63:763-771. doi: 10.2340/1651-226X.2024.40324.
4
Postoperative Complications of Upfront Ovarian Cancer Surgery and Their Effects on Chemotherapy Delay.卵巢癌初次手术的术后并发症及其对化疗延迟的影响。
Curr Oncol. 2024 Sep 19;31(9):5630-5642. doi: 10.3390/curroncol31090417.
5
Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study.血清肿瘤标志物在评估晚期卵巢癌新辅助化疗疗效中的临床价值:单中心前瞻性临床研究
Front Oncol. 2024 May 28;14:1399502. doi: 10.3389/fonc.2024.1399502. eCollection 2024.
6
Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease.对接受初次肿瘤细胞减灭术的卵巢癌患者进行全基因组关联分析,以确定残留疾病的候选基因。
NPJ Genom Med. 2024 Mar 5;9(1):19. doi: 10.1038/s41525-024-00395-y.
7
MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.MAD2L2,一种在卵巢癌中起关键调节作用的蛋白,促进肿瘤的进展。
Sci Rep. 2024 Jan 2;14(1):130. doi: 10.1038/s41598-023-50744-7.
8
Preoperative prediction of miliary changes in the small bowel mesentery in advanced high-grade serous ovarian cancer using MRI radiomics nomogram.使用MRI影像组学列线图对晚期高级别浆液性卵巢癌小肠系膜粟粒样改变进行术前预测。
Abdom Radiol (NY). 2023 Mar;48(3):1119-1130. doi: 10.1007/s00261-023-03802-7. Epub 2023 Jan 18.